Genomics of Brain Disorders 2026 | Opening keynote by Matt Hurles, Wellcome Sanger Institute, UK

Value of the Information & Strength of the Argument

The talk provides high-value information by synthesizing over 15 years of research from the DDD project and new unpublished data. The argumentation is rigorous: Hurles builds a coherent narrative from diagnostic yield to genetic architecture, then to functional models and future directions. He clearly distinguishes between established findings (e.g., 40% diagnostic yield, de novo mutation prevalence) and emerging hypotheses (e.g., longitudinal effects of rare vs. polygenic variants). The reasoning is supported by large sample sizes (180,000 trios) and statistical models (mutation rate null hypothesis, burden analyses). The speaker acknowledges uncertainties, such as the incomplete understanding of VUS and the role of environmental factors. The argument for international collaboration and the need for population cohorts is well-justified. The talk avoids oversimplification, presenting complex interactions like parental assortment and liability threshold models. Overall, the value lies in its comprehensive, data-driven synthesis and transparent discussion of limitations.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high: the talk is based on peer-reviewed studies (e.g., DDD project, ALSPAC cohort) and large-scale international collaborations. Sources are not explicitly cited in the transcript, but the speaker references specific projects and colleagues (Caroline Wright, Hillary Martin). The title accurately reflects the content, covering both discovery and functional genomics of brain disorders. The keynote format ensures the speaker’s authority, and the data presented are robust. No commercial bias is evident. The talk’s alignment with the conference theme is clear, and the title’s broad scope is justified by the breadth of topics covered.

The title accurately reflects the content: the talk covers genomic discovery of neurodevelopmental disorder genes, cellular and mouse models, and functional follow-up. The title is broad but appropriate for a keynote.

9/10

Keynote delivered by a leading researcher at a major genomics institute, based on large-scale international datasets (180,000 trios, DDD cohort) and published work. The speaker explicitly distinguishes published from unpublished data and acknowledges limitations and uncertainties. No commercial bias detected.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction and overview of the talk: discovery of NDD genes, cellular and mouse models, unpublished data.
• 03:00Description of the DDD project: 14,000 families, 200 clinicians, diagnostic feedback system.
• 07:00Diagnostic yield: 40% of children receive a diagnosis, with de novo mutations in three-quarters of cases.
• 10:00Factors predicting diagnosis: sex bias, trio recruitment, severity, prenatal risk factors, ancestry bias.
• 15:00Genetic architecture: contribution of de novo, recessive, X-linked, and polygenic variation.
• 20:00Polygenic risk and its correlation with educational attainment and schizophrenia; parental assortment.
• 25:00Longitudinal effects: rare variant impact on IQ decreases with age, polygenic effects increase.
• 30:00Population differences: recessive burden in South Asian ancestry linked to parental relatedness.
• 35:00Discovery of new genes: 180,000 trios, haploinsufficient genes, ribosomal proteins.
• 40:00Unpublished functional work: cellular models of 38 NDDs and 16 mouse lines, chromatinopathies.